There are a few treatments and medication available to treat the male pattern baldness condition
Because Saxenda acts peripherally and centrally on metabolic pathways, whilst sertraline modulates neurotransmitter activity, their primary therapeutic targets do not overlap, reducing the likelihood of direct pharmacological interaction
So for an employer who is willing to invest in these agents with the objective of making their workforce healthier, even if the drugs drop to a hundred and fifty dollars PMPM, which is what Im hearing for oral agents, its still a significant investment given the percentage of the population struggling with this condition
Its important to explore all available options, such as insurance coverage, manufacturer discounts, and patient assistance programs, to help make the treatment more affordable
However, there are no guarantees